Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Verizon Communications Inc (VZ) Price & Performance

Crispr Therapeutics AGTrade
Verizon Communications IncTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Verizon Communications Inc — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while Verizon Communications Inc trades at $46.96 (market cap $196.40B). The key difference: Verizon Communications Inc is far larger — about 37.6× Crispr Therapeutics AG's market cap, and Verizon Communications Inc pays a 5.99% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

CRSPVZ
Market Cap
$5.23B$196.40B
Sector
HealthMedia
52-Week High
$76.78$51.38
52-Week Low
$44.34$38.40
Enterprise Value
$3.65B$383.10B
Volume
22,584,735
Dividend Yield
5.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.

Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.

Verizon Communications Inc

Verizon (VZ) trades at $46.93, down slightly by 0.21% on the day, with a bullish technical signal from moving averages. The company shows stable fundamentals with $138.19B in 2025 revenue and consistent earnings beats in recent quarters. Recent news highlights network expansion initiatives and strategic partnerships, including a fiber deal with Alphabet. Cash flow improved significantly in 2025 with $14.86B net cash flow, though debt levels remain elevated at $121.38B long-term.

VZ presents a value opportunity with a P/E of 12.31 below sector average and strong dividend yield. Analyst consensus targets $49.69 with 36.7% buy ratings, though competition from SpaceX's Starlink and high debt pose risks. The stock's current price near support at $47 suggests limited downside if technical levels hold.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About Verizon Communications Inc

Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.

Read more on VZ